Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Harvard Business School
Express Scripts
Mallinckrodt

Last Updated: May 27, 2022

Investigational Drug Information for Avigan


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Avigan?

Avigan is an investigational drug.

There have been 17 clinical trials for Avigan. The most recent clinical trial was a Phase 2 trial, which was initiated on August 20th 2020.

The most common disease conditions in clinical trials are COVID-19, Hemorrhagic Fever, Ebola, and Lassa Fever. The leading clinical trial sponsors are Novagenix Bioanalytical Drug R&D Center, Farmagen Ar-Ge Biyot. Ltd. Sti, and Institut National de la Santé Et de la Recherche Médicale, France.

There are one hundred and thirty-two US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Avigan
TitleSponsorPhase
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa FeverAlliance for International Medical ActionPhase 2
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa FeverFederal Medical Centre, OwoPhase 2
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa FeverInstitut National de la Santé Et de la Recherche Médicale, FrancePhase 2

See all Avigan clinical trials

Clinical Trial Summary for Avigan

Top disease conditions for Avigan
Top clinical trial sponsors for Avigan

See all Avigan clinical trials

US Patents for Avigan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Avigan See Plans and Pricing Methods and compositions for inhibition of polymerase BioCryst Pharmaceuticals, Inc. (Durham, NC) See Plans and Pricing
Avigan See Plans and Pricing Methods of preparing inhibitors of influenza viruses replication Vertex Pharmaceuticals Incorporated (Boston, MA) See Plans and Pricing
Avigan See Plans and Pricing Viral prophylaxis treatment methods and pre-exposure prophylaxis kits ELIAN LLC (Monrovia, CA) See Plans and Pricing
Avigan See Plans and Pricing Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Avigan

Drugname Country Document Number Estimated Expiration Related US Patent
Avigan Australia AU2011315902 2030-10-15 See Plans and Pricing
Avigan Australia AU2017200471 2030-10-15 See Plans and Pricing
Avigan Brazil BR112013009029 2030-10-15 See Plans and Pricing
Avigan Canada CA2813783 2030-10-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Harvard Business School
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.